RxDoctor Payments Data

Savitha Bharadwaj, MD

Internal Medicine · Irvine, CANPI 1760470926

Payments from drug & device makers

$3,114in general payments, 2019–2025

Across 248 payments — averaging $12.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$534
  • AstraZeneca$476
  • GSK$350
  • Lilly USA, LLC$346
  • Amgen$310
  • Takeda Pharmaceuticals U.S.A., Inc.$209
  • plus $889 from 15 others

What the payments were for

  • Food & beverage$3,108100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,114 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$81,820
Medicare patients
221
Services billed
892

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide41$46,316
JardianceEmpagliflozin19$23,753
MyrbetriqMirabegron11$15,247
SynthroidLevothyroxine Sodium34$2,732
Levothyroxine Sodium149$2,148
Atorvastatin Calcium177$1,432
Losartan Potassium116$1,416
Rosuvastatin Calcium99$1,313
Bupropion XlBupropion Hcl41$1,248
Amlodipine Besylate180$909
Nebivolol Hcl12$856
Omeprazole61$849
Metoprolol Succinate37$779
Metformin Hcl93$704
Albuterol Sulfate HfaAlbuterol Sulfate31$701

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$534$46,31641 claims
Boehringer IngelheimJardiance$107$23,75319 claims
Astellas Pharma US IncMyrbetriq$185$15,24711 claims
AbbVieSynthroid$69$2,73234 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Irvine

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →